| Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases MP Mazanetz, PM Fischer Nature reviews Drug discovery 6 (6), 464-479, 2007 | 630 | 2007 |
| Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice JA Moreno, M Halliday, C Molloy, H Radford, N Verity, JM Axten, CA Ortori, ... Science translational medicine 5 (206), 206ra138-206ra138, 2013 | 627 | 2013 |
| In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) SJ McClue, D Blake, R Clarke, A Cowan, L Cummings, PM Fischer, ... International journal of cancer 102 (5), 463-468, 2002 | 477 | 2002 |
| Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity M Halliday, H Radford, Y Sekine, J Moreno, N Verity, J Le Quesne, ... Cell death & disease 6 (3), e1672-e1672, 2015 | 334 | 2015 |
| Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology S Wang, PM Fischer Trends in pharmacological sciences 29 (6), 302-313, 2008 | 293 | 2008 |
| Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics PM Fischer, DP Lane Current medicinal chemistry 7 (12), 1213-1245, 2000 | 267 | 2000 |
| Diketopiperazines in peptide and combinatorial chemistry PM Fischer Journal of peptide science: an official publication of the European Peptide …, 2003 | 252 | 2003 |
| Mutations in a translation initiation factor identify the target of a memory-enhancing compound Y Sekine, A Zyryanova, A Crespillo-Casado, PM Fischer, HP Harding, ... Science 348 (6238), 1027-1030, 2015 | 229 | 2015 |
| Structure–activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin PM Fischer, NZ Zhelev, S Wang, JE Melville, R Fåhraeus, DP Lane The Journal of peptide research 55 (2), 163-172, 2000 | 221 | 2000 |
| 4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects V Kryštof, P Cankař, I Fryšová, J Slouka, G Kontopidis, P Džubák, ... Journal of medicinal chemistry 49 (22), 6500-6509, 2006 | 220 | 2006 |
| Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation PM Fischer, E Krausz, DP Lane Bioconjugate chemistry 12 (6), 825-841, 2001 | 201 | 2001 |
| 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity S Wang, C Meades, G Wood, A Osnowski, S Anderson, R Yuill, M Thomas, ... Journal of medicinal chemistry 47 (7), 1662-1675, 2004 | 197 | 2004 |
| CDK inhibitors in clinical development for the treatment of cancer PM Fischer, A Gianella-Borradori Expert opinion on investigational drugs 12 (6), 955-970, 2003 | 187 | 2003 |
| The design, synthesis and application of stereochemical and directional peptide isomers: a critical review PM Fischer Current Protein and Peptide Science 4 (5), 339-356, 2003 | 186 | 2003 |
| Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B AF Zyryanova, F Weis, A Faille, AA Alard, A Crespillo-Casado, Y Sekine, ... Science 359 (6383), 1533-1536, 2018 | 185 | 2018 |
| Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding S Uhrinova, D Uhrin, H Powers, K Watt, D Zheleva, P Fischer, C McInnes, ... Journal of molecular biology 350 (3), 587-598, 2005 | 184 | 2005 |
| Recent progress in the discovery and development of cyclin-dependent kinase inhibitors PM Fischer, A Gianella-Borradori Expert opinion on investigational drugs 14 (4), 457-477, 2005 | 181 | 2005 |
| Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines A Zgair, JCM Wong, JB Lee, J Mistry, O Sivak, KM Wasan, IM Hennig, ... American journal of translational research 8 (8), 3448, 2016 | 163 | 2016 |
| The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases PM Fischer Current medicinal chemistry 11 (12), 1563-1583, 2004 | 160 | 2004 |
| Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop SY Wu, I McNae, G Kontopidis, SJ McClue, C McInnes, KJ Stewart, ... Structure 11 (4), 399-410, 2003 | 160 | 2003 |
Nikolai ZhelevProfessor of Medical Biotechnology, University of Abertay DundeeVerified email at abertay.ac.uk
